Availability and accessibility of cytotoxic medicines in the WHO model list of essential medicines for childhood cancer in low and lower-middle- income countries: a systematic review

Abstract Background Socio-economic inequalities significantly impact paediatric cancer survival. The review aims to elucidate the facilitators and barriers influencing the availability and accessibility of essential medicines for childhood cancer (EMCC) in low- and lower-middle-income countries (LLM...

Full description

Saved in:
Bibliographic Details
Main Authors: Maheeka Seneviwickrama, Sashini Shehana Denagamagei, Surangi Jayakody, Sanjeeva Gunasekera, Guwani Liyanage
Format: Article
Language:English
Published: BMC 2025-01-01
Series:BMC Cancer
Subjects:
Online Access:https://doi.org/10.1186/s12885-025-13586-2
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832571615841353728
author Maheeka Seneviwickrama
Sashini Shehana Denagamagei
Surangi Jayakody
Sanjeeva Gunasekera
Guwani Liyanage
author_facet Maheeka Seneviwickrama
Sashini Shehana Denagamagei
Surangi Jayakody
Sanjeeva Gunasekera
Guwani Liyanage
author_sort Maheeka Seneviwickrama
collection DOAJ
description Abstract Background Socio-economic inequalities significantly impact paediatric cancer survival. The review aims to elucidate the facilitators and barriers influencing the availability and accessibility of essential medicines for childhood cancer (EMCC) in low- and lower-middle-income countries (LLMICs). Methods This systematic review was conducted adhering to the PRISMA guidelines. Peer- reviewed primary studies, national/regional reports, and policy documents published in the English language were included through a thorough literature search using three electronic databases: MEDLINE, EMBASE, and CINAHL. Review questions were framed according to the ECLIPS framework. Children under 19 years of age living in LLMICs diagnosed with any malignancy were the client group. The quality of the included studies was assessed using the mixed methods appraisal tool. Data is presented as a narrative synthesis. Enablers and barriers were discussed based on the World Health Organization (WHO) health system building blocks. Results Out of the 29 articles retrieved for full-text screening, the final synthesis included nine articles. Six were based on quantitative, two on mixed-method research, and one was a review article. These studies represented 26 LLMICs from several continents (Africa, Asia, and America). The alignment of the National Essential Medicine Lists (NEMLs) with the World Health Organization Essential Medicine List for Children (WHO EMC) varied from 40%- 60%. Overall stock out rate ranged from 17 to 100%. Stock out rate was higher in the public sector than in the private sector. International partnerships, policy changes, and financing strategies are some of the key enablers identified. Barriers included inadequate global drug production, high drug costs, weak regulatory enforcement, poor supply chain management, and insufficient health information systems. Conclusion The findings of our review revealed the failure of LLMICs to meet the WHO- recommended target of 80% availability for EMCCs. The availability and accessibility of EMCC in LLMICs are hindered by multiple systemic barriers despite several enabling strategies. Addressing these challenges requires coordinated global efforts and local initiatives to ensure equitable access to childhood cancer treatments in LLMICs. PROSPERO registration number CRD42022334156.
format Article
id doaj-art-cbef980862444163a582e6b525abf6df
institution Kabale University
issn 1471-2407
language English
publishDate 2025-01-01
publisher BMC
record_format Article
series BMC Cancer
spelling doaj-art-cbef980862444163a582e6b525abf6df2025-02-02T12:28:50ZengBMCBMC Cancer1471-24072025-01-0125111710.1186/s12885-025-13586-2Availability and accessibility of cytotoxic medicines in the WHO model list of essential medicines for childhood cancer in low and lower-middle- income countries: a systematic reviewMaheeka Seneviwickrama0Sashini Shehana Denagamagei1Surangi Jayakody2Sanjeeva Gunasekera3Guwani Liyanage4Centre for Cancer Research, University of Sri JayewardenepuraCentre for Cancer Research, University of Sri JayewardenepuraDepartment of Community Medicine, Faculty of Medical Sciences, University of Sri JayewardenepuraDepartment of Paediatric Oncology, National Cancer Institute Sri LankaDepartment of Paediatrics, Faculty of Medical Sciences, University of Sri JayewardenepuraAbstract Background Socio-economic inequalities significantly impact paediatric cancer survival. The review aims to elucidate the facilitators and barriers influencing the availability and accessibility of essential medicines for childhood cancer (EMCC) in low- and lower-middle-income countries (LLMICs). Methods This systematic review was conducted adhering to the PRISMA guidelines. Peer- reviewed primary studies, national/regional reports, and policy documents published in the English language were included through a thorough literature search using three electronic databases: MEDLINE, EMBASE, and CINAHL. Review questions were framed according to the ECLIPS framework. Children under 19 years of age living in LLMICs diagnosed with any malignancy were the client group. The quality of the included studies was assessed using the mixed methods appraisal tool. Data is presented as a narrative synthesis. Enablers and barriers were discussed based on the World Health Organization (WHO) health system building blocks. Results Out of the 29 articles retrieved for full-text screening, the final synthesis included nine articles. Six were based on quantitative, two on mixed-method research, and one was a review article. These studies represented 26 LLMICs from several continents (Africa, Asia, and America). The alignment of the National Essential Medicine Lists (NEMLs) with the World Health Organization Essential Medicine List for Children (WHO EMC) varied from 40%- 60%. Overall stock out rate ranged from 17 to 100%. Stock out rate was higher in the public sector than in the private sector. International partnerships, policy changes, and financing strategies are some of the key enablers identified. Barriers included inadequate global drug production, high drug costs, weak regulatory enforcement, poor supply chain management, and insufficient health information systems. Conclusion The findings of our review revealed the failure of LLMICs to meet the WHO- recommended target of 80% availability for EMCCs. The availability and accessibility of EMCC in LLMICs are hindered by multiple systemic barriers despite several enabling strategies. Addressing these challenges requires coordinated global efforts and local initiatives to ensure equitable access to childhood cancer treatments in LLMICs. PROSPERO registration number CRD42022334156.https://doi.org/10.1186/s12885-025-13586-2AvailabilityAccessibilityEssential medicine listChildhood cancerLower income and lower-middle-income countriesWHO model list
spellingShingle Maheeka Seneviwickrama
Sashini Shehana Denagamagei
Surangi Jayakody
Sanjeeva Gunasekera
Guwani Liyanage
Availability and accessibility of cytotoxic medicines in the WHO model list of essential medicines for childhood cancer in low and lower-middle- income countries: a systematic review
BMC Cancer
Availability
Accessibility
Essential medicine list
Childhood cancer
Lower income and lower-middle-income countries
WHO model list
title Availability and accessibility of cytotoxic medicines in the WHO model list of essential medicines for childhood cancer in low and lower-middle- income countries: a systematic review
title_full Availability and accessibility of cytotoxic medicines in the WHO model list of essential medicines for childhood cancer in low and lower-middle- income countries: a systematic review
title_fullStr Availability and accessibility of cytotoxic medicines in the WHO model list of essential medicines for childhood cancer in low and lower-middle- income countries: a systematic review
title_full_unstemmed Availability and accessibility of cytotoxic medicines in the WHO model list of essential medicines for childhood cancer in low and lower-middle- income countries: a systematic review
title_short Availability and accessibility of cytotoxic medicines in the WHO model list of essential medicines for childhood cancer in low and lower-middle- income countries: a systematic review
title_sort availability and accessibility of cytotoxic medicines in the who model list of essential medicines for childhood cancer in low and lower middle income countries a systematic review
topic Availability
Accessibility
Essential medicine list
Childhood cancer
Lower income and lower-middle-income countries
WHO model list
url https://doi.org/10.1186/s12885-025-13586-2
work_keys_str_mv AT maheekaseneviwickrama availabilityandaccessibilityofcytotoxicmedicinesinthewhomodellistofessentialmedicinesforchildhoodcancerinlowandlowermiddleincomecountriesasystematicreview
AT sashinishehanadenagamagei availabilityandaccessibilityofcytotoxicmedicinesinthewhomodellistofessentialmedicinesforchildhoodcancerinlowandlowermiddleincomecountriesasystematicreview
AT surangijayakody availabilityandaccessibilityofcytotoxicmedicinesinthewhomodellistofessentialmedicinesforchildhoodcancerinlowandlowermiddleincomecountriesasystematicreview
AT sanjeevagunasekera availabilityandaccessibilityofcytotoxicmedicinesinthewhomodellistofessentialmedicinesforchildhoodcancerinlowandlowermiddleincomecountriesasystematicreview
AT guwaniliyanage availabilityandaccessibilityofcytotoxicmedicinesinthewhomodellistofessentialmedicinesforchildhoodcancerinlowandlowermiddleincomecountriesasystematicreview